UI Hospitals and Clinics
90Y-DOTA-tyr 3 Octreotide with or without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults: A Randomized, Placebo controlled Phase II Trial with Dosimetry Guided Dosing of 90Y -DOTA-tyr 3 Octreotide (60)
Participants in this study have been diagnosed with neuroblastoma or a neuroendocrine tumor. The purpose of this research study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta® in treating your neuroblastoma or neuroendocrine tumor. Approximately 60 people will take part in this study conducted by investigators at the University of Iowa. Study involvement is life long with treatment lasting approximately 18-24 weeks.
M. Sue O'Dorisio, 319-356-7873
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.